RESUMO
Bioelectrochemical systems are emerging technologies for the reduction in CO2 in fuels and chemicals, in which anaerobic chemoautotrophic microorganisms such as methanogens and acetogens are typically used as biocatalysts. The anaerobic digestion digestate represents an abundant source of methanogens and acetogens microorganisms. In a mixed culture environment, methanogen's inhibition is necessary to avoid acetate consumption by the presence of acetoclastic methanogens. In this study, a methanogenesis inhibition approach based on the thermal treatment of mixed cultures was adopted and evaluated in terms of acetate production under different tests consisting of hydrogenophilic and bioelectrochemical experiments. Batch experiments were carried out under hydrogenophilic and bioelectrochemical conditions, demonstrating the effectiveness of the thermal treatment and showing a 30 times higher acetate production with respect to the raw anaerobic digestate. Moreover, a continuous flow bioelectrochemical reactor equipped with an anion exchange membrane (AEM) successfully overcomes the methanogens reactivation, allowing for a continuous acetate production. The AEM membrane guaranteed the migration of the acetate from the biological compartment and its concentration in the abiotic chamber avoiding its consumption by acetoclastic methanogenesis. The system allowed an acetate concentration of 1745 ± 30 mg/L in the abiotic chamber, nearly five times the concentration measured in the cathodic chamber.
RESUMO
Every year cardiovascular diseases kill the highest number of people worldwide. Among these, pathologies characterized by sporadic symptoms, such as atrial fibrillation, are difficult to be detected as state-of-the-art solutions, e.g., 12-leads electrocardiogram (ECG) or Holter devices, often fail to tackle these kinds of pathologies. Many portable devices have already been proposed, both in literature and in the market. Unfortunately, they all miss relevant features: they are either not wearable or wireless and their usage over a long-term period is often unsuitable. In addition, the quality of recordings is another key factor to perform reliable diagnosis. The ECG WATCH is a device designed for targeting all these issues. It is inexpensive, wearable (size of a watch), and can be used without the need for any medical expertise about positioning or usage. It is non-invasive, it records single-lead ECG in just 10 s, anytime, anywhere, without the need to physically travel to hospitals or cardiologists. It can acquire any of the three peripheral leads; results can be shared with physicians by simply tapping a smartphone app. The ECG WATCH quality has been tested on 30 people and has successfully compared with an electrocardiograph and an ECG simulator, both certified. The app embeds an algorithm for automatically detecting atrial fibrillation, which has been successfully tested with an official ECG simulator on different severity of atrial fibrillation. In this sense, the ECG WATCH is a promising device for anytime cardiac health monitoring.
